These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 23539269)

  • 1. Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN.
    Bjerke L; Mackay A; Nandhabalan M; Burford A; Jury A; Popov S; Bax DA; Carvalho D; Taylor KR; Vinci M; Bajrami I; McGonnell IM; Lord CJ; Reis RM; Hargrave D; Ashworth A; Workman P; Jones C
    Cancer Discov; 2013 May; 3(5):512-9. PubMed ID: 23539269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. G34, another connection between MYCN and a pediatric tumor.
    Huang M; Weiss WA
    Cancer Discov; 2013 May; 3(5):484-6. PubMed ID: 23658294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glioblastoma: histone mutations take the MYCN.
    McCarthy N
    Nat Rev Cancer; 2013 Jun; 13(6):382-3. PubMed ID: 23615692
    [No Abstract]   [Full Text] [Related]  

  • 4. Altered global histone-trimethylation code and H3F3A-ATRX mutation in pediatric GBM.
    Pathak P; Jha P; Purkait S; Sharma V; Suri V; Sharma MC; Faruq M; Suri A; Sarkar C
    J Neurooncol; 2015 Feb; 121(3):489-97. PubMed ID: 25479829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.
    Schwartzentruber J; Korshunov A; Liu XY; Jones DT; Pfaff E; Jacob K; Sturm D; Fontebasso AM; Quang DA; Tönjes M; Hovestadt V; Albrecht S; Kool M; Nantel A; Konermann C; Lindroth A; Jäger N; Rausch T; Ryzhova M; Korbel JO; Hielscher T; Hauser P; Garami M; Klekner A; Bognar L; Ebinger M; Schuhmann MU; Scheurlen W; Pekrun A; Frühwald MC; Roggendorf W; Kramm C; Dürken M; Atkinson J; Lepage P; Montpetit A; Zakrzewska M; Zakrzewski K; Liberski PP; Dong Z; Siegel P; Kulozik AE; Zapatka M; Guha A; Malkin D; Felsberg J; Reifenberger G; von Deimling A; Ichimura K; Collins VP; Witt H; Milde T; Witt O; Zhang C; Castelo-Branco P; Lichter P; Faury D; Tabori U; Plass C; Majewski J; Pfister SM; Jabado N
    Nature; 2012 Jan; 482(7384):226-31. PubMed ID: 22286061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebral hemispheric glioblastoma with PNET-like morphology and histone H3.3 G34 mutation in younger patients: Report of three rare cases and diagnostic pitfalls.
    Cheng Y; Bao W; Wu Q
    Indian J Pathol Microbiol; 2020; 63(2):262-266. PubMed ID: 32317528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas.
    Venneti S; Garimella MT; Sullivan LM; Martinez D; Huse JT; Heguy A; Santi M; Thompson CB; Judkins AR
    Brain Pathol; 2013 Sep; 23(5):558-64. PubMed ID: 23414300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.
    Sturm D; Witt H; Hovestadt V; Khuong-Quang DA; Jones DT; Konermann C; Pfaff E; Tönjes M; Sill M; Bender S; Kool M; Zapatka M; Becker N; Zucknick M; Hielscher T; Liu XY; Fontebasso AM; Ryzhova M; Albrecht S; Jacob K; Wolter M; Ebinger M; Schuhmann MU; van Meter T; Frühwald MC; Hauch H; Pekrun A; Radlwimmer B; Niehues T; von Komorowski G; Dürken M; Kulozik AE; Madden J; Donson A; Foreman NK; Drissi R; Fouladi M; Scheurlen W; von Deimling A; Monoranu C; Roggendorf W; Herold-Mende C; Unterberg A; Kramm CM; Felsberg J; Hartmann C; Wiestler B; Wick W; Milde T; Witt O; Lindroth AM; Schwartzentruber J; Faury D; Fleming A; Zakrzewska M; Liberski PP; Zakrzewski K; Hauser P; Garami M; Klekner A; Bognar L; Morrissy S; Cavalli F; Taylor MD; van Sluis P; Koster J; Versteeg R; Volckmann R; Mikkelsen T; Aldape K; Reifenberger G; Collins VP; Majewski J; Korshunov A; Lichter P; Plass C; Jabado N; Pfister SM
    Cancer Cell; 2012 Oct; 22(4):425-37. PubMed ID: 23079654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of H3.3G34V mutation on genomic H3K36 and H3K27 methylation patterns in isogenic pediatric glioma cells.
    Huang TY; Piunti A; Qi J; Morgan M; Bartom E; Shilatifard A; Saratsis AM
    Acta Neuropathol Commun; 2020 Dec; 8(1):219. PubMed ID: 33287886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin.
    Gallo M; Coutinho FJ; Vanner RJ; Gayden T; Mack SC; Murison A; Remke M; Li R; Takayama N; Desai K; Lee L; Lan X; Park NI; Barsyte-Lovejoy D; Smil D; Sturm D; Kushida MM; Head R; Cusimano MD; Bernstein M; Clarke ID; Dick JE; Pfister SM; Rich JN; Arrowsmith CH; Taylor MD; Jabado N; Bazett-Jones DP; Lupien M; Dirks PB
    Cancer Cell; 2015 Dec; 28(6):715-729. PubMed ID: 26626085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone H3.3 G34 Mutations Alter Histone H3K36 and H3K27 Methylation In Cis.
    Shi L; Shi J; Shi X; Li W; Wen H
    J Mol Biol; 2018 May; 430(11):1562-1565. PubMed ID: 29689253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A lesson learned from the H3.3K27M mutation found in pediatric glioma: a new approach to the study of the function of histone modifications in vivo?
    Chan KM; Han J; Fang D; Gan H; Zhang Z
    Cell Cycle; 2013 Aug; 12(16):2546-52. PubMed ID: 23907119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity.
    Korshunov A; Capper D; Reuss D; Schrimpf D; Ryzhova M; Hovestadt V; Sturm D; Meyer J; Jones C; Zheludkova O; Kumirova E; Golanov A; Kool M; Schüller U; Mittelbronn M; Hasselblatt M; Schittenhelm J; Reifenberger G; Herold-Mende C; Lichter P; von Deimling A; Pfister SM; Jones DT
    Acta Neuropathol; 2016 Jan; 131(1):137-46. PubMed ID: 26482474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
    Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J
    Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers.
    Korshunov A; Schrimpf D; Ryzhova M; Sturm D; Chavez L; Hovestadt V; Sharma T; Habel A; Burford A; Jones C; Zheludkova O; Kumirova E; Kramm CM; Golanov A; Capper D; von Deimling A; Pfister SM; Jones DTW
    Acta Neuropathol; 2017 Sep; 134(3):507-516. PubMed ID: 28401334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation.
    Jha P; Pia Patric IR; Shukla S; Pathak P; Pal J; Sharma V; Thinagararanjan S; Santosh V; Suri V; Sharma MC; Arivazhagan A; Suri A; Gupta D; Somasundaram K; Sarkar C
    Neuro Oncol; 2014 Dec; 16(12):1607-17. PubMed ID: 24997139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
    Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
    Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.
    Valentijn LJ; Koster J; Haneveld F; Aissa RA; van Sluis P; Broekmans ME; Molenaar JJ; van Nes J; Versteeg R
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19190-5. PubMed ID: 23091029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-localization of the oncogenic transcription factor MYCN and the DNA methyl binding protein MeCP2 at genomic sites in neuroblastoma.
    Murphy DM; Buckley PG; Das S; Watters KM; Bryan K; Stallings RL
    PLoS One; 2011; 6(6):e21436. PubMed ID: 21731748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
    Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
    PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.